Women with hard-to-treat ovarian cancer could benefit from a life-extending drug on the NHS. The targeted therapy – mirvetuximab soravtansine – will be offered to patients living with ovarian cancer whose disease has stopped responding to standard (platinum-based) chemotherapy, providing new hope of extra time to live.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.
Create a network to share documents, knowledge and best practice with your colleagues. Set up a network to keep in touch with other people in your organisation or with shared interest groups across organisational boundaries.
Networks can be open to all or available only to a closed group defined by the administrator.
Join or create a network here.
